Deal Snapshot
Allergan Aesthetics to Acquire Soliton for USD 550m
Monday 17 May 2021

US-based aesthetics brands and products company Allergan Aesthetics, an AbbVie Company (NYSE: ABBV) and US-based medical device maker Soliton (NASDAQ: SOLY) have inked a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device, the companies said.

Resonic recently received US Food and Drug Administration 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition of Soliton expands and complements Allergan Aesthetics' Body Contouring treatment portfolio which includes CoolSculpting Elite.

Date Published: 17/05/2021